Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Other Non Operating Income (2020 - 2025)

Oncology Institute (TOI) has disclosed Other Non Operating Income for 6 consecutive years, with -$6.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non Operating Income fell 46076.92% year-over-year to -$6.0 million, compared with a TTM value of -$13.5 million through Sep 2025, down 2881.06%, and an annual FY2024 reading of -$365000.0, up 48.15% over the prior year.
  • Other Non Operating Income was -$6.0 million for Q3 2025 at Oncology Institute, down from -$4.0 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.3 million in Q1 2023 and bottomed at -$6.0 million in Q3 2025.
  • Average Other Non Operating Income over 5 years is -$983727.3, with a median of -$151000.0 recorded in 2022.
  • The sharpest move saw Other Non Operating Income surged 2297.35% in 2023, then crashed 46076.92% in 2025.
  • Year by year, Other Non Operating Income stood at -$54000.0 in 2021, then tumbled by 179.63% to -$151000.0 in 2022, then tumbled by 131.79% to -$350000.0 in 2023, then increased by 25.43% to -$261000.0 in 2024, then tumbled by 2190.04% to -$6.0 million in 2025.
  • Business Quant data shows Other Non Operating Income for TOI at -$6.0 million in Q3 2025, -$4.0 million in Q2 2025, and -$3.3 million in Q1 2025.